Published in Tumori on June 11, 2007
Tonsillar metastasis of gastric cancer. Clin J Gastroenterol (2010) 0.87
Oculomotor Paralysis, Postorbital Pain, and Hypopituitarism as First Presentations of Metastatic Gastric Cancer in the Pituitary Flourished by Internal Carotid Aneurysm: A Case Report. Medicine (Baltimore) (2015) 0.79
Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol (2012) 2.64
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst (2008) 1.95
Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. Breast Cancer Res Treat (2009) 1.86
Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. Acta Neuropathol (2010) 1.82
HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res (2008) 1.63
Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Clin Cancer Res (2010) 1.57
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer (2011) 1.53
Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol (2011) 1.52
The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial. Breast Cancer Res Treat (2010) 1.50
Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst (2009) 1.47
Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer. Clin Breast Cancer (2004) 1.46
Management of triple negative breast cancer. Breast (2010) 1.43
Metabolomics: available results, current research projects in breast cancer, and future applications. J Clin Oncol (2007) 1.42
Equivalence between ovarian suppression and chemotherapy in the adjuvant treatment of endocrine-responsive breast cancer. J Clin Oncol (2002) 1.39
Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol (2009) 1.34
Breast cancer assessment tools and optimizing adjuvant therapy. Nat Rev Clin Oncol (2010) 1.32
CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol (2014) 1.28
Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer. Breast Cancer Res (2009) 1.28
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat (2012) 1.26
Targeting triple negative breast cancer: is p53 the answer? Cancer Treat Rev (2013) 1.23
Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther (2004) 1.17
Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: a critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol (2003) 1.13
Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res (2005) 1.13
Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study. Clin Breast Cancer (2002) 1.11
The reproducibility of CIN diagnoses among different pathologists: data from histology reviews from a multicenter randomized study. Am J Clin Pathol (2009) 1.10
Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. J Clin Oncol (2009) 1.07
DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. Oncologist (2013) 1.04
Uncovering the metabolomic fingerprint of breast cancer. Int J Biochem Cell Biol (2010) 1.04
Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. Mol Cancer Ther (2006) 1.03
Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res (2008) 1.02
HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact. Cancer Treat Rev (2013) 1.00
The risk of false-positive histology according to the reason for colposcopy referral in cervical cancer screening: a blind revision of all histologic lesions found in the NTCC trial. Am J Clin Pathol (2008) 0.99
Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98. Psychooncology (2013) 0.97
Immune recovery after autologous stem cell transplantation is not different for HIV-infected versus HIV-uninfected patients with relapsed or refractory lymphoma. Clin Infect Dis (2010) 0.96
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. Breast Cancer Res Treat (2012) 0.96
Predicting anthracycline benefit: have we made any progress? Curr Opin Oncol (2009) 0.95
The nutritional risk in oncology: a study of 1,453 cancer outpatients. Support Care Cancer (2012) 0.95
Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). Eur J Cancer (2007) 0.94
Real-time PCR analysis of RNA extracted from formalin-fixed and paraffin-embeded tissues: effects of the fixation on outcome reliability. Appl Immunohistochem Mol Morphol (2007) 0.93
Resistance to trastuzumab: a necessary evil or a temporary challenge? Clin Breast Cancer (2002) 0.92
Clinical value of Epstein-Barr virus DNA levels in peripheral blood samples of Italian patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Lett (2006) 0.92
Exploration of serum metabolomic profiles and outcomes in women with metastatic breast cancer: a pilot study. Mol Oncol (2012) 0.92
Breast cancer in the elderly: which lessons have we learned? Future Oncol (2013) 0.90
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278). Clin Breast Cancer (2008) 0.89
Case report: long-term survival of an infant syndromic patient affected by atypical teratoid-rhabdoid tumor. BMC Cancer (2013) 0.88
Feasibility of evaluating quality cancer care using registry data and electronic health records: a population-based study. Int J Qual Health Care (2012) 0.88
Expression of estrogen receptor beta in colon cancer progression. Diagn Mol Pathol (2008) 0.87
Type A microsatellite instability in pediatric gliomas as an indicator of Turcot syndrome. Eur J Hum Genet (2009) 0.87
Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy. Curr Opin Oncol (2014) 0.87
Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up? Ecancermedicalscience (2013) 0.86
Interferon-gamma secretion and perforin expression are impaired in CD8+ T lymphocytes from patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother (2002) 0.86
Polyendocrine treatment in estrogen receptor-positive breast cancer: a "FACT" yet to be proven. J Clin Oncol (2012) 0.86
International study on inter-reader variability for circulating tumor cells in breast cancer. Breast Cancer Res (2014) 0.86
Late solitary metastasis of cutaneous malignant melanoma presenting as abnormal uterine bleeding. J Obstet Gynaecol Res (2008) 0.85
Hemangioma of the umbilical cord: report of a case. Pathol Res Pract (2003) 0.85
Role of lapatinib in the first-line treatment of patients with metastatic breast cancer. Cancer Manag Res (2010) 0.85
Good interobserver and intraobserver agreement in the evaluation of the new ILAE classification of focal cortical dysplasias. Epilepsia (2012) 0.85
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers. BMC Med (2015) 0.84
Assessment of immunovirological features in HIV related non-Hodgkin lymphoma patients and their impact on outcome. J Clin Virol (2012) 0.84
The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. Cancer Treat Rev (2009) 0.83
Smooth muscle cells, dendritic cells and mast cells are sources of TNFalpha and nitric oxide in human carotid artery atherosclerosis. Thromb Res (2008) 0.83
The efficacy of lapatinib in metastatic breast cancer with HER2 non-amplified primary tumors and EGFR positive circulating tumor cells: a proof-of-concept study. PLoS One (2013) 0.83
Large-muscle endometriosis involving the adductor tight compartment: case report. J Minim Invasive Gynecol (2010) 0.83
Quantitative expression of the homeobox and integrin genes in human gastric carcinoma. Int J Mol Med (2007) 0.83
Intrinsic epileptogenicity of gangliogliomas may be independent from co-occurring focal cortical dysplasia. Epilepsy Res (2011) 0.83
Chemotherapy for metastatic breast cancer. Curr Opin Obstet Gynecol (2004) 0.82
Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology. Breast Cancer Res Treat (2013) 0.82
Monotherapy with thalidomide for treatment of spinal cord hemangioblastomas in a patient with von Hippel-Lindau disease. Pediatr Blood Cancer (2009) 0.82
Triple negative breast cancer: a heterogeneous subgroup defined by what it is not. Eur J Cancer (2011) 0.82
Intracranial mesenchymal chondrosarcoma: report of two pediatric cases. Pediatr Blood Cancer (2010) 0.82
An incidentally detected third ventricle chordoid glioma. Neurol India (2007) 0.82
Extensive deep vein thrombosis as a complication of testicular cancer treated with the BEP protocol (bleomycin, etoposide and cisplatin): case report. Sao Paulo Med J (2006) 0.82
Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. Tumori (2012) 0.81
Chorangiosis: report of three cases and review of the literature. Pathol Res Pract (2003) 0.81
NF2 expression levels of gastrointestinal stromal tumors: a quantitative real-time PCR study. Tumori (2008) 0.81
Intramedullary spinal cord metastasis from synovial sarcoma. Case illustration. J Neurosurg Spine (2008) 0.81
The continued evidence from overviews: what is the clinical utility? Breast (2013) 0.81
Adjuvant systemic treatment for individual patients with triple negative breast cancer. Breast (2011) 0.80
Predictive value of HIV type 1 DNA levels on overall survival in HIV-related lymphoma Patients treated with high-dose chemotherapy (HDC) plus autologous stem cell transplantation (ASCT). AIDS Res Hum Retroviruses (2010) 0.80
Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors. Oncol Rep (2009) 0.80
The Epstein Barr virus DNA levels as a tumor marker in EBV-associated cancers. J Cancer Res Clin Oncol (2007) 0.80
Anthracyclines: the first generation of cytotoxic targeted agents? A possible dream. J Clin Oncol (2008) 0.79
Controversies in the adjuvant systemic therapy of endocrine-non-responsive breast cancer. Cancer Treat Rev (2002) 0.79
Oncocytic meningiomas: Cases with benign histopathological features and a favorable clinical course. J Neurosurg (2006) 0.79
Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer. Curr Med Res Opin (2010) 0.79
Sickle cell-related bone marrow complications: the utility of diffusion-weighted magnetic resonance imaging. J Pediatr Hematol Oncol (2013) 0.78
Autograft HIV-DNA load predicts HIV-1 peripheral reservoir after stem cell transplantation for AIDS-related lymphoma patients. AIDS Res Hum Retroviruses (2015) 0.78
Adjuvant chemotherapy--the dark side of clinical trials. Have we learnt more? Breast (2009) 0.78
Multiplex analysis of blood cytokines as a prognostic tool in HIV related non-Hodgkin lymphoma patients: a potential role of interleukin-7. Cytokine (2012) 0.78
TNM staging and T-cell receptor gamma expression in colon adenocarcinoma. Correlation with disease progression? Tumori (2008) 0.78
Expression of β-adrenergic receptors in pediatric malignant brain tumors. Oncol Lett (2012) 0.78
Metastatic spread outside the central nervous system of anaplastic medulloblastoma associated with a spinal-peritoneal shunt immediately after radiotherapy. Pediatr Neurosurg (2011) 0.78
Serum antibody response to lytic and latent Epstein-Barr virus antigens in undifferentiated nasopharyngeal carcinoma patients from an area of nonendemicity. Clin Vaccine Immunol (2007) 0.77
Significance of micrometastases: circulating tumor cells and disseminated tumor cells in early breast cancer. Cancers (Basel) (2010) 0.77
Intracerebral atypical presentation of echinococcosis in a child. Pediatr Neurosurg (2008) 0.77
Levonorgestrel-releasing intrauterine system alone as primary treatment in young women with early endometrial cancer: case report. J Minim Invasive Gynecol (2009) 0.77